

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over [ID4024]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

The following potential equality issues were highlighted during the scoping process:

- Vamorolone has been studied in clinical trials in boys aged 4 years and older.
- At consultation it was noted that corticosteroids are not routinely used or recommended in female carriers, even if symptomatic.
- At the workshop clinicians expressed that they would prescribe vamorolone to girls diagnosed with Duchenne muscular dystrophy unless there were clear reasons not to.
- Stakeholders also noted concerns about travel distance to receive treatment given the level of disability many patients have.

Age and gender are protected under the Equality Act 2010. But because its recommendation does not restrict access to treatment for some people over others, the committee agreed this was not a potential equalities issue.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other potential equality issues have been identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, the draft recommendations do not recommend the technology

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, the draft recommendations do not recommend the technology

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, in Section 3.22

Approved by Associate Director (name): Ian Watson

Date: 20/03/2024